212631-85-1

Basic information

• Product Name: Benzoic acid, 5-bromo-2,3,4-trifluoro-
• CAS NO: 212631-85-1
• Molecular Formula: C7H2BrF3O2
• Molecular Weight: 254.991
• Mol File: 212631-85-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-bromo-2,3,4-trifluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-bromo-2,3,4-trifluoro-(212631-85-1)
• EPA Substance Registry System: Benzoic acid, 5-bromo-2,3,4-trifluoro-(212631-85-1)

Safety Data

• Hazardous Substances Data: 212631-85-1(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 5-bromo-2,3,4-trifluoro- is a compound that belongs to the class of organic compounds known as benzoic acids. It is a derivative of benzoic acid, with bromine and trifluoromethyl groups attached to the benzene ring. Benzoic acid, 5-bromo-2,3,4-trifluoro- is commonly used as an intermediate for the synthesis of pharmaceuticals and agrochemicals, as well as in the production of dyes and pigments. It is considered to be a chemical intermediate and building block for organic synthesis, with potential applications in various industries. Additionally, it is important to handle this compound with care, as it may pose health and safety risks in its handling and use.

Upstream product

• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 124-38-9 carbon dioxide 
• 530145-56-3 (5-bromo-2,3,4-trifluorophenyl)triethylsilane 
• 176317-02-5 1-bromo-2,3,4-trifluorobenzene 
• 1489-53-8 1,2,3-trifluorobenzene 
• 530145-57-4 1-bromo-2,3,4-trifluoro-5-iodobenzene 

Downstream Products

• 212628-46-1 5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid 
• 530145-59-6 methyl 3-bromo-4,5,6-trifluorobenzoate 
• 847372-97-8 5-bromo-3,4-difluoro-2-((2-chlorophenyl)amino)benzoic acid 
• 1040246-49-8 5-bromo-3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid 
• 1448441-56-2 5-((4-bromo-2-chlorophenyl)amino)-N-(2,3-dihydroxypropoxy)-4-fluorobenzo[d]oxazole-6-carboxamide 
• 853246-58-9 methyl 5-bromo-3,4-difluoro-2-((2-fluorophenyl)amino)benzoate 

Relevant articles and documents

Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold

Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB). To overcome the BBB, both passive permeability and efflux transporter liability of a compound must be addressed. Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases. Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed. In addition to determining inhibitor potency and selectivity, crystal structures of most newly designed compounds complexed to various nitric oxide synthase isoforms have been determined. We have discovered a new analogue (21), which exhibits not only excellent potency (Ki 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.

BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF

Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical compositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.

INHIBITORS OF MEK

This invention concerns to N-(2-aylamino) aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.